HUTCHMED (China) Limited Sponsored ADR (HCM)
(Delayed Data from NSDQ)
$18.12 USD
-0.52 (-2.79%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $18.15 +0.03 (0.17%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
HCM 18.12 -0.52(-2.79%)
Will HCM be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for HCM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HCM
HUTCHMED (HCM) Upgraded to Buy: Here's What You Should Know
Does HUTCHMED (HCM) Have the Potential to Rally 38.13% as Wall Street Analysts Expect?
HCM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 75.05% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
After Plunging -10.7% in 4 Weeks, Here's Why the Trend Might Reverse for HUTCHMED (HCM)
Wall Street Analysts See a 107.24% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
Other News for HCM
IN BRIEF: Hutchmed (China) begins trial of menin inhibitor HMPL-506
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
HUTCHMED Tests New Leukemia Drug in Phase I Trial
What's Driving HUTCHMED (China) Ltd's Surprising 17% Stock Rally?
Hutchmed announces FRUTIGA results published in Nature Medicine